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TheMycobacterium avium-M. intracellulare complex (MAC) causes a pulmonary disease (PD) similar to tuberculosis (TB). Di-
agnosis of MAC-PD is complicated and time-consuming. In this study, the serodiagnostic potential of the newly identified
MAV2054 andMAV5183 proteins was evaluated in subjects withMAC-PD, pulmonary TB, or latent TB and in noninfected
healthy controls (HC), together with HspX and the 38-kDa antigen, well-known serodiagnosticM. tuberculosis antigens. All four
antigens evoked significantly higher IgG responses inMAC-PD and active TB than in latent TB and HC subjects. Among the an-
tigens, MAV2054 elicited the highest antibody responses in pulmonary TB andMAC-PD patients. IgG titers against MAV2054
andMAV5183 were significantly higher inMAC-PD than in pulmonary TB subjects. In addition, the levels of IgG against all an-
tigens in theM. intracellulare and fibrocavitary forms were higher than those in theM. avium and nodular bronchiectatic
forms, respectively. Based on sensitivity and receiver operator characteristic curve analysis, the best candidates for detection of
MAC-PD and pulmonary TB were MAV2054 and the 38-kDa antigen, respectively. In total, 76.0% of MAC-PD and 65.0% of ac-
tive TB patients were reactive to at least two antigens. In contrast, only 2.8% of HC subjects were reactive with two or more anti-
gens. Our findings suggest that an enzyme-linked immunosorbent assay (ELISA) using the four antigens would be valuable for
screening for mycobacterial lung disease, includingMAC-PD and pulmonary TB, although it does not provide good discrimina-
tion of the disease-causing pathogens.
More than 100 species are recognized in the genusMycobacte-rium, and other than the two well-known mycobacterial
species Mycobacterium tuberculosis and M. leprae, most are ubiq-
uitous in the environment in soil, dust, plants, natural waters,
food, and biofilms (1–3). These mycobacteria, previously known
as atypical mycobacteria, are now more commonly called nontu-
berculous mycobacteria (NTM). The pathogens most commonly
associated with NTM disease are the M. avium complex (MAC),
M. abscessus, andM. kansasii (4). NTM can cause chronic pulmo-
nary disease (PD) in humans similar to slowly progressive pulmo-
nary tuberculosis (TB), but unlike tuberculosis, infection byNTM
is not transmitted from person to person. Currently, the diagnosis
of NTM-PD remains a challenge due to the complex diagnostic
criteria, and the management of NTM-PD is difficult due to the
prolonged treatment duration and resistance to antimycobacterial
drugs (5).
MAC is the most common cause of NTM lung diseases and is
an opportunistic infectious agent encountered frequently in pa-
tients who are immunocompromised, such as individuals with
human immunodeficiency virus (HIV) infection (6). Further-
more, the prevalence of MAC-PD in immunocompetent patients
has increased recently (5). The diagnosis of MAC-PD is compli-
cated and time-consuming, becauseMACmay colonize the respi-
ratory tract, and the isolation of MAC from sputum specimens
often has no clinical or microbiologic significance due to its ubiq-
uity in nature. In addition, discrimination of MAC-PD from pul-
monary TB is difficult. Although the American Thoracic Society
(ATS) has outlined guidelines for the diagnosis of NTM, the diag-
nosis of MAC-PD requires combined clinical, radiographic, and
microbiologic evidence (5). Therefore, there have been many ef-
forts to overcome these difficulties in diagnosis of MAC-PD.
There have been few attempts to develop a serologic test for
diagnosis of MAC-PD and to distinguish it from other lung dis-
eases, such as TB (7). Serodiagnostic tests using multiple myco-
bacterial antigens (Ag) are attractive for diagnosis of the disease
due to their simplicity and economics. Use of glycopeptidolipids
(GPLs) as markers for differentiation of MAC-PD from pulmo-
nary TB and other mycobacterial infections has been reported
(8–11). However, mycobacterial glycolipids, such as GPL and
cord factor, are difficult to purify in quantity, and their prepara-
tion requires great labor and is associated with a high cost. M.
avium KatG is the only protein reported as a novel diagnostic
marker of M. avium infection (12). Therefore, identification of
seroreactive proteins fromMAC culture filtrate and evaluation of
their usefulness to distinguish MAC-PD from pulmonary TB or
healthy controls (HC) still need to be investigated more exten-
sively.
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We previously reported the serodiagnostic potential of a my-
cobacterial antigen cocktail for detection of TB using an enzyme-
linked immunosorbent assay (ELISA) (13). In the present study,
to apply the combined ELISA for serologic diagnosis ofMAC-PD,
we identified two candidates, MAV2054 and MAV5183, by
screening using multidimensional fractionation ofM. avium cul-
ture filtrate proteins (CFP) and probing with sera from patients
with MAC-PD. In addition, HspX and 38-kDa protein (PstS1),
well-known serodiagnostic M. tuberculosis antigens, were in-
cluded in the antibody detection assay. The serodiagnostic poten-
tial of all four antigens was evaluated in subjects with MAC-PD,
pulmonary TB, or latent TB and in HC.MAV2054 andMAV5183
proteins elicited significantly higher antibody responses in
MAC-PD than in pulmonary TB and HC subjects.
MATERIALS AND METHODS
Subjects. Sera were obtained from 175 patients with MAC-PD (median
age 60 years; age range 27 to 85 years; percentage ofmales, 38%), 123
with active pulmonary TB (median age 52 years; age range 18 to 91
years; percentage of males, 63%), 151 with latent TB infection (LTBI) as
defined by positive tuberculin skin test (TST) results (median age  22
years; age range 14 to 63 years; percentage of males, 54%), and 141 HC
as defined by negative TST results (median age 23 years; age range 8
to 69 years; percentage of males, 62%). A total of 175 MAC patients who
satisfied the diagnostic criteria of the American Thoracic Society (ATS)
(5) were prospectively enrolled at the Asan Medical Center (Seoul, South
Korea) or SamsungMedical Center (Seoul, South Korea). All serum sam-
ples obtained fromMAC-PDpatients from the two hospitals were accom-
panied by information about the isolated disease-causing bacteria (M.
avium orM. intracellulare), while some included more-detailed informa-
tion regarding TST results or diagnosis of one of two distinct subtypes, the
nodular bronchiectatic form or fibrocavitary form, on the basis of radio-
graphic features as identified by chest computed tomography.
Sera were obtained from patients with active TB or MAC-PD either
before or during the first 2 weeks of medication. A basic diagnosis of TB
was determined by acid-fast bacillus (AFB) staining and culture results as
well as clinical evaluation, such as chest X-ray. Of 123 pulmonary TB sera,
97 were smear or culture positive and 26 were smear and culture negative.
Colonies were identified asM. tuberculosis orM. avium complex using the
AccuProbe test (Gen-Probe Inc., San Diego, CA) or a duplex PCR kit
(M&D,Wonju, South Korea). MAC species were identified using a PCR-
restriction fragment length polymorphism method, based on the rpoB
gene (14).
Serum samples from LTBI patients were selected from the healthy
participants from the Asan Medical Center based on TST results, includ-
ing or not including a history of previous TB disease or exposure to risk
factors for TB. TSTswere performedusing 2 tuberculin units (TU) of PPD
RT23 (Statens Serum Institute, Copenhagen, Demark) and the Mantoux
method (15), and induration size was measured after 48 to 72 h using the
ballpoint method. An induration diameter of more than 10 mm was re-
garded as a positive result, and consequently, sera from a total of 151
individuals with positive TST results and 141 HC with negative TST re-
sults and no history of clinical TB were collected. In addition, an gamma
interferon release assay (IGRA) in some subjects with MAC-PD or LTBI
and in HC was performed using QuantiFERON-TB Gold (QFT-G; Cell-
estis Ltd., Carnegie, Victoria, Australia) (16). All serum samples were
collected after written informed consent had been provided by partici-
pants, and the study protocol was approved by the Institutional Review
Board (IRB) of the Asan Medical and Samsung Medical Centers.
Multidimensional fractionationofCFP.TheM.avium 104 strainwas
grown for 6 weeks at 37°C as surface pellicles on Sauton’s medium as
described previously (17, 18). Culture filtrate proteins (CFP) were filter
sterilized and concentrated by ultrafiltration (Amicon Ultra centrifugal
filter unit with 3-kDa molecular mass cutoff; Millipore, Bedford, MA).
Multidimensional fractionation was performed as described previously
(19). In brief, the CFPwas precipitated with ammonium sulfate (50% and
80% saturation). The resulting precipitates were dissolved in 50 mM po-
tassium phosphate buffer (PB) containing 1 M ammonium sulfate, and
then were separated by hydrophobic interaction chromatography (HIC)
using phenyl Sepharose (GEHealthcare Biosciences, Piscataway, NJ) with
a linear decreasing gradient of 1 to 0Mammonium sulfate–50mMPBand
further eluted with 1 mM PB. Each eluate fraction was divided into three
subfractions according to its major band pattern upon resolution by so-
dium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
Each of the primary fractions was concentrated separately, dialyzed
against 1 mM PB, and then was further fractionated by hydroxyapatite
chromatography with elution using a gradient of 1 to 300 mM PB. The
eluate was pooled into individual subfractions according to its protein
band pattern and concentrated. A third fractionation step was performed
using diethylaminoethanol (DEAE) ion-exchange chromatography and a
linear salt gradient of 0 to 300 mM NaCl–20 mM Tris-HCl (pH 8.0). All
pooled fractions were concentrated and stored at70°C until use.
Protein identification.Themajor bands of the different fractions that
strongly reacted with sera from patients with MAC-PD were selected and
subjected to liquid chromatography-electrospray ionization-mass spec-
trometry (LC-ESI-MS) at the Yonsei Proteomics Research Center (Yonsei
University, Seoul, South Korea) as described previously (13, 17).
Preparation of recombinant proteins. For this study, four recombi-
nant antigens, the newly identified MAC proteins, MAV2054 and
MAV5183, and the well-characterizedM. tuberculosis proteins HspX and
38-kDa, were prepared. TheHspX and 38-kDa proteins were produced in
Escherichia coli and purified as described previously (13).
To produce MAV2054 and MAV5183, the corresponding genes were
amplified by PCR usingM. avium 104 genomic DNA as the template and
the following primers: MAV2054-forward, 5=-CATATGACGTCGGCTC
AAAATGAGTCT-3=; MAV2054-reverse, 5=-AAGCTTCTTGTACTCAT
GGAACTGATC-3=; MAV5183-forward, 5=-CATATGTCCAAGCCGGG
GCTTCCGGTG-3=; and MAV5183-reverse, 5=-AAGCTTGGTGGCGGG
CTGGGCGGGTTG-3=. Using the Signal P 4.0 server (http://www.cbs.dtu
.dk/services/SignalP), which predicts the presence and location of
N-terminal signal peptide cleavage sites within amino acid sequences,
MAV5183 was determined to be a secretory protein with a putative signal
sequence. Therefore, MAV5183 was amplified by PCR without the for-
ward primer, which covered the sequence for secretion. Each PCR prod-
uct was cut with NdeI and HindIII and then inserted into the pET22b()
vector (Novagen, Madison, WI). The recombinant proteins were overex-
pressed in E. coli BL21 cells carrying bacteriophage DE3 and were purified
by nickel-nitrilotriacetic acid (Ni-NTA) affinity chromatography in ac-
cordance with the manufacturer’s instructions (Qiagen, Chatsworth,
CA). The purified protein was pooled, concentrated, and dialyzed against
phosphate-buffered saline (PBS; pH 7.4). Lastly, purified recombinant
proteins were filter sterilized and stored at70°C. Protein concentration
was estimated using a bicinchoninic acid protein assay kit (Pierce, Rock-
ford, IL) with bovine serum albumin (BSA) as the standard.
ELISA. An enzyme-linked immunosorbent assay (ELISA) was per-
formed as described previously (20). Briefly, the recombinant antigens (1
g/ml) were diluted in a coating buffer (KPL, Inc., Gaithersburg, MD),
and 100l was added to each well in 96-well microtiter plates (Maxisorp;
Nalge Nunc International, Rochester, NY). After overnight incubation at
4°C, the plates were washed three times with 1 washing buffer (KPL,
Inc.), and then the wells were blocked with 5% BSA–PBS at room tem-
perature for 3 h. After three more washes, 100 l/well human serum
(1:200 dilution) was added to each plate, and the plates were incubated at
room temperature for 1 h. Afterwashing, 100l of peroxidase-conjugated
goat anti-human IgG (Sigma-Aldrich, St. Louis,MO) at a 1:6,000 dilution
was added to each well. The plates were then incubated for an additional
30min at room temperature. After sevenmore washes, the reactions were
developed with a 5-mg o-phenylenediamine (OPD) tablet (Sigma) in 12
ml of substrate buffer and 0.05M phosphate-citrate buffer followed by 12
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l of 30%H2O2. The reaction was stopped with 2 N sulfuric acid after 20
min of incubation in the dark. The optical density (OD) was measured at
490 nm (OD490) with an ELISA microplate reader (Molecular Devices,
Sunnyvale, CA).
Evaluation of tests and statistical analysis. In this study, there were
more than 100 individuals in each subject group; therefore, we considered
that the statistical data followed a normal distribution, regardless of the
results of the normality test. The mean plus standard deviation (SD) of
each group was used as the parameter, and values are expressed as the
meanOD SD.We used themeans plus 2 SDof control subjects as cutoff
values for distinguishing between a positive and negative result. For as-
sessment of the significance of differences among the four groups, mean
differences were evaluated by a receiver operator characteristic (ROC)
curve analysis andTukey’smultiple-comparison one-way analysis of vari-
ance (ANOVA). Differences in the median ODs of sera in the MAC-PD
and LTBI subgroups were evaluated by the nonparametric Mann-Whit-
ney test. Most statistical analyses were performed using Prism software,
version 4.03 (GraphPad Software, San Diego, CA).
RESULTS
Identification of theMAV2054 andMAV5183 proteins. It is im-
portant to identify and test serologically active mycobacterial an-
tigens to determine the most appropriate mixture of antigens for
serodiagnosis. Therefore, we conducted broad-scale fractionation
of CFP ofM. avium and determined seroreactivity by ELISA. The
CFP was fractionated through a sequential multistep chromato-
graphic process that included hydrophobic interaction, hydroxy-
apatite, and ion exchange. IgG titers against all fractions in the sera
of some patients with MAC-PD or active pulmonary TB and of
HCwere determined by ELISA. IgG titers against fraction 15 (F15)
and F30 inMAC-PDpatients were significantly higher than inHC
or active TBpatients. Furthermore, the sensitivities of F15 and F30
for diagnosis of MAC-PD were 50% and 62.5%, respectively,
which were higher than those of the other fractions. The major
protein bands contained in F15 and F30 were selected for identi-
fication, and the two proteins indicated by rectangular boxes in
Fig. 1 were subjected to LC-tandem MS (LC-MS/MS) analysis.
The proteins with the highest scoring match to the query and the
highest amino acid sequence homology were MAV2054 and
MAV5183, respectively.
Purification of the recombinant proteins. The newly identi-
fied MAV2054 and MAV5183 proteins were expressed as 6His-
tagged recombinant proteins in E. coli strain BL21 and then puri-
fied byNi-NTA affinity chromatography. Due to the presence of a
signal sequence at the N terminus of MAV5183, recombinant
MAV5183 without the signal peptide (47 amino acids) was pro-
duced. The purity of both recombinant proteins was confirmed by
SDS-PAGE (Fig. 2).
Overall seroreactive patterns of the four proteins. To inves-
tigate the serodiagnostic potential of the newly identified MAC
proteins, serum IgG levels against each protein were measured in
patients with MAC-PD, pulmonary TB, or LTBI and in HC. The
HspX and 38-kDa antigen, well-knownTB antigens that were pre-
pared anddescribed previously (13), were also included. As shown
in Table 1 and in Fig. S1 in the supplemental material, all four
antigens evoked significantly higher IgG responses in the
MAC-PD and pulmonary TB groups than in the LTBI and HC
groups. Among the antigens, MAV2054 elicited the highest anti-
body responses in pulmonary TB aswell asMAC-PDpatients. IgG
titers against MAV2054 and MAV5183, but not HspX or 38-kDa
antigen, were significantly different between the MAC-PD and
pulmonary TB groups. However, MAC-PD and pulmonary TB
patients reacted with both the TB andMAC antigens to consider-
able levels. In addition, antibody titers against the other three
antigens were not significantly different between LTBI and HC
subjects. There were no significant differences between smear- or
culture-positive subjects and smear- and culture-negative subjects
(data not shown).
Considering the mean plus 2 SD of HC as a cutoff value and a
specificity of 94 to 97% for all antigens, MAV2054 showed the
highest sensitivity for diagnosis of MAC-PD. Sensitivity of
MAV2054 and the 38-kDa antigen for pulmonary TB was higher
than that of the other two antigens. In general, the sensitivity of all
antigens for diagnosis of MAC-PD was higher than that for pul-
monary TB. MAV2054 for MAC-PD and 38-kDa antigen for pul-
monary TB showed the highest areas under the concentration-
time curve, respectively, compared to the other antigens. Taken
FIG 1 Identification of strong MAV2054 and MAV5183 seroreactivity in
MAC-PD patients. An ammonium sulfate precipitate of M. avium CFP was
fractionated by hydrophobic interaction chromatography using phenyl Sep-
harose. Each of the primary fractions was further fractionated by hydroxya-
paptite chromatography. The third fractionation was conducted by DEAE
ion-exchange chromatography. IgG titers in all fractions of sera from MAC-
PD, pulmonary TB, and HC subjects were determined by ELISA. Two frac-
tions, F15 (A) and F30 (B), were selected, subjected to SDS-PAGE, and stained
with Coomassie brilliant blue.
FIG 2 SDS-PAGE analysis of purified recombinant MAV2054 (A) and
MAV5183 (B) proteins. The proteins were overexpressed in E. coli, purified by
Ni-NTA affinity chromatography, and analyzed by SDS-PAGE with Coomas-
sie brilliant blue staining. Each lane was loaded with 20 g protein. Bars indi-
cate molecular mass.
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together, these results suggest that the best candidates for the di-
agnosis of MAC-PD and active TB are MAV2054 and the 38-kDa
antigen, respectively.
Antibody responses according to TST or IGRA results.There
were no significant differences between HspX, the 38-kDa anti-
gen, and MAV5183 in the LTBI (tuberculin reactor) and HC (tu-
berculin nonreactor) group results. However, it is possible that
MAC-PD patients recognized the TB antigens due to coinfection
withM. tuberculosis. To determine this, TST and IGRA were per-
formed in suspect MAC-PD cases. A subset of the MAC-PD pa-
tients was classified into two groups on the basis of their TST or
IGRA positivity. As shown in Table 2, no significant differences
were observed in the IgG responses to any antigen between the
TST- or IGRA-positive and TST- or IGRA-negative groups. These
results suggest that cross-reactivity to the four antigens between
MAC-PD and TB patients may be due to the similarity of serore-
active epitopes among the antigens, rather than coinfection.
In this study, discrimination of the LTBI and HC groups was
based on TST results. In addition, IGRA was performed in some
subjects with LTBI; these were divided into IGRA-positive and
-negative groups for comparison of their antibody responses. In-
terestingly, the median antibody level of the IGRA-positive group
was higher than that of the IGRA-negative group (see Table S1 in
the supplemental material). In particular, significant differences
in IgG titers against MAV2054 and HspX between the IGRA-pos-
itive and -negative groups were observed. Additionally, the sensi-
tivities of all antigens in the IGRA-positive group were signifi-
cantly higher than in the IGRA-negative group.
Antibody responses among MAC-PD subgroups. The 175
MAC-PD patients were divided into two subgroups according to
the presence of disease-causing bacteria,M. avium (48%; n 84)
andM. intracellulare (52%; n 91). As shown in Table 3, levels of
IgG for all antigens in theM. intracellulare groupwere higher than
those in theM. avium group. In particular, significant differences
in IgG titers against MAV5183 and the 38-kDa antigen between
the groups were observed. Furthermore, the sensitivity of
MAV5183 and the 38-kDa antigen for theM. intracellulare group
was higher than that for theM. avium group.
The 89 MAC-PD patients for whom detailed radiographic in-
formation was available were classified into two subgroups: those
with the nodular bronchiectatic formof the disease and thosewith
the fibrocavitary form. Interestingly, the median antibody levels
against MAV2054, MAV5183, and the 38-kDa antigen of the fi-T
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TABLE 2 Comparison of IgG responses to mycobacterial antigens
among MAC-PD subjects according to TST and IGRA resultsa
Antigen
ELISA result for MAC-PD (n 71)
TST or IGRA positive
(n 34)
TST and IGRA negative
(n 24)
Median titer
(IQR)
% sensitivity
(no. of
positive
samples)
Median titer
(IQR)
% sensitivity
(no. of
positive
samples)
MAV2054 0.540 (0.30–0.70) 61.8 (21) 0.480 (0.28–0.69) 54.2 (13)
MAV5183 0.308 (0.23–0.45) 50.0 (17) 0.392 (0.29–0.50) 58.3 (14)
HspX 0.309 (0.20–0.43) 50.0 (17) 0.316 (0.27–0.41) 50.0 (12)
38-kDa 0.142 (0.11–0.21) 44.1 (15) 0.131 (0.10–0.21) 62.5 (15)
a IQR, interquartile range between 25th and 75th percentile. There were no differences
between the TST- or IGRA-positive group and TST- and IGRA-negative group by a
Mann-Whitney test that compared two unpaired groups (P 0.05).
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brocavitary group were significantly higher than those of the nod-
ular bronchiectatic group, and the sensitivity of these three anti-
gens for the fibrocavitary group was markedly higher than for the
nodular bronchiectatic group (Table 3).
Effect of antigen combination on sensitivity. To investigate
the multiple-antigen reactivity of a subject, we analyzed the fre-
quency of reactivity against the four antigens in individual sub-
jects (see Table S2 in the supplemental material). Of the 175
MAC-PD patients, 91 (52.0%) showed reactivity to two or more
antigens. Of the 123 serum samples from active TB patients, 40
(32.5%) were reactive to two or more antigens. In contrast, only
8/151 (5.3%) LTBI and 4/141 (2.8%)HC subjects were reactive to
two or more antigens.
Next, we compared reactivity to a single antigen or to com-
bined antigens in each group (Table 4). As expected, combina-
tions of two or more antigens had higher diagnostic sensitivity for
each patient group than use of a single antigen alone. Using a
combination of two antigens, the sensitivity was the highest with
MAV2054 plus the 38-kDa antigen. The combination of
MAV2054, the 38-kDa antigen, andMAV5183 resulted in the best
diagnostic performance in terms of combinations of three anti-
gens. When four antigens were combined, sensitivities of 65.0%
for active TB, 76.0% for MAC-PD, and 26.5% for LTBI resulted,
with a specificity of 83%.
DISCUSSION
The rates of recovery of NTM from AFB smear-positive clinical
specimens have increased worldwide, and NTM is responsible for
an increasing proportion of mycobacterial disease in many devel-
oped countries (21, 22).WhenNTMare cultured and identified in
respiratory specimens, a diagnosis of NTM lung disease requires
differentiation between contamination and colonization (23).
Thus, serological reactivity facilitates the diagnosis of such dis-
eases. Differentiation of NTM lung disease from pulmonary TB is
important to the clinician. MAC is the most common cause of
NTM lung disease in most regions of the world. Although exten-
sive studies to identify protein antigens suitable for serodiagnosis
of TB have been performed, little effort has focused on identifica-
tion and evaluation of protein antigens for diagnosis of NTM lung
disease. Here we evaluated serologic responses to newly identified
M. avium proteins (MAV2054 and MAV5183) and well-known
M. tuberculosis proteins (HspX and the 38-kDa protein) in pa-
tients with MAC-PD or pulmonary TB and in HC. Interestingly,
the newly identified MAV2054 elicited the highest antibody re-
sponses in both TB and MAC-PD patients.
The HspX and 38-kDa proteins reacted with sera from
MAC-PD to levels similar to their reactivities with sera from active
TB patients. One possible explanation for this apparent cross-
TABLE 3 Comparison of IgG responses to mycobacterial antigens according MAC-PD typea
Antigen
Pathogen of MAC-PDb (n 175) Radiographic findings of MAC-PDc (n 89)
M. avium (n 84) M. intracellulare (n 91) Nodular bronchiectasis (n 69) Fibrocavitary (n 20)
Median titer
(IQR)
% sensitivity
(no. of
positive
samples)
Median titer
(IQR)
% sensitivity
(no. of
positive
samples)
Median titer
(IQR)
% sensitivity
(no. of
positive
samples)
Median titer
(IQR)
% sensitivity
(no. of
positive
samples)
MAV2054 0.459 (0.20–0.65)c 51.2 (43) 0.471 (0.31–0.74)c 52.7 (48) 0.389 (0.22–0.54)e 40.6 (28) 0.489 (0.28–0.68)f 60.0 (12)
MAV5183 0.251 (0.15–0.44)c 36.9 (31) 0.337 (0.23–0.51)d 50.5 (46) 0.203 (0.12–0.39)e 27.5 (19) 0.379 (0.22–0.85)f 65.0 (13)
HspX 0.233 (0.14–0.37)c 31.0 (26) 0.266 (0.20–0.35)c 39.6 (36) 0.208 (0.14–0.30)e 23.2 (16) 0.216 (0.18–0.27)e 15.0 (03)
38-kDa 0.100 (0.06–0.15)c 26.2 (22) 0.160 (0.11–0.30)d 61.5 (56) 0.107 (0.07–0.17)e 34.8 (24) 0.196 (0.11–0.45)f 60.0 (12)
a Values indicated by superscript roman letters (“c” and “d” for comparisons betweenM. avium andM. intracellulare data and “e” and “f” for comparisons between nodular
bronchiectasis and fibrocavitary data) represent significant differences according to a Mann-Whitney test that compared two unpaired groups (P 0.05).
b Classification by the disease-causing mycobacteria.
c Classification by the characteristic radiologic finding.
TABLE 4 Effects of antigen combinations on sensitivity
Antigen(s)
% sensitivity (no. of positive sera)
% specificity (no. of positive sera)
for HC (n 141)
MAC-PD
(n 175)
Pulmonary TB
(n 123)
LTBI
(n 151)
HspX 35.4 (62) 24.4 (30) 5.3 (8) 94.3 (8)
38-kDa 44.6 (78) 35.8 (44) 10.6 (16) 95.0 (7)
MAV2054 52.0 (91) 35.8 (44) 13.2 (20) 96.5 (5)
MAV5183 44.0 (77) 24.4 (30) 5.3 (8) 95.7 (6)
38-kDaHspX 57.1 (100) 48.8 (60) 15.2 (23) 89.4 (15)
38-kDaMAV5183 61.7 (108) 45.5 (56) 15.2 (23) 90.8 (13)
38-kDaMAV2054 67.4 (118) 56.9 (70) 21.9 (33) 91.5 (12)
MAV2054MAV5183 62.9 (110) 46.3 (57) 15.2 (23) 92.2 (11)
NAV2054MAV5183HspX 66.3 (116) 51.2 (63) 17.9 (27) 87.9 (17)
38-kDaHspXMAV5183 68.6 (120) 56.1 (69) 18.5 (28) 85.1 (21)
38-kDaHspXMAV2054 71.4 (125) 59.3 (73) 24.5 (37) 87.2 (18)
38-kDaMAV2054MAV5183 74.3 (130) 61.8 (76) 23.8 (36) 87.2 (18)
38-kDaHspXMAV2054MAV5183 76.0 (133) 65.0 (80) 26.5 (40) 83.0 (24)
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reactivity is M. tuberculosis coinfection in MAC-PD patients.
However, there was no significant difference in antibody re-
sponses to any antigen tested in TST-positive and -negative
MAC-PD patients. MAC contains phosphate-binding protein,
which is similar to the 38-kDa protein (PstS1) of M. tuberculosis,
and alpha crystallin family protein, which is similar to HspX
(Rv2031c, alpha crystallin). Our results suggest that epitopes con-
tained in both proteins may also be present in MAC proteins.
Therefore, when TB is diagnosed serologically using M. tubercu-
losis proteins, it is possible that the presence ofMAC-PDmay lead
to false-positive results.
The newly identified MAV2054 and MAV5183 proteins elic-
ited significantly higher antibody responses in the MAC-PD
group than in those with pulmonary TB. However, considerable
reactivity against both antigens in active TBwas also observed. On
an amino acid level, MAV2054 shares 100% homology with 35-
kDa major membrane protein 1 (MMP-1) of M. avium subsp.
paratuberculosis (MAP) and shows 92% identity and 97% positiv-
ity with respect to the MMP of M. leprae. MMP-1, which was
originally discovered inM. leprae as a 35-kDa immunodominant
protein (24), is a serodiagnostic antigen that elicits strong hu-
moral immune responses in tuberculoid leprosy (25–27). In ad-
dition, the gene that encodes this protein is present inM. abscessus
andM. massiliense; however, it is absent from other mycobacteria
such as M. tuberculosis and M. bovis bacillus Calmette-Guérin
(BCG) (27, 28). The MAV5183 gene encodes antigen 85C
(Ag85C), which consists of the antigen 85 complex ofM. tubercu-
losis (29). Ag85C was reported as a seroreactive protein in TB (30,
31) and is highly conserved amongmostmycobacteria except sev-
eral species of NTM such asM. fortuitum orM. chelonae. In addi-
tion, MAV5183 had 85% amino acid sequence identity and 93%
homology with M. tuberculosis. Therefore, seroreactivity against
MAV2054 and MAV5183 in TB patients may due to the presence
of similar epitopes in the variousM. tuberculosis proteins or due to
frequent exposure to MAC, which is ubiquitous in nature.
GPL is used extensively as an antigen for serodiagnosis of
MAC-PD and differential diagnosis from pulmonary TB (7–9).
GPLs are major components of the outer layer of many NTM cell
envelopes and are serotype specific. In addition, GPLs are not
present in the M. tuberculosis complex (32). Therefore, a combi-
nationmultiple-lipid antigen ELISA that includes GPL (7) and an
enzyme immunoassay (EIA) kit detecting serum IgA antibody
specific forGPL core (8)were useful for diagnosis ofMAC-PDand
for differentiating MAC-PD from pulmonary TB. However,
24.8%of TB patients and only 4.2%ofHC subjects were anti-GPL
IgG positive (7). Those data and our results suggest that cross-
reactivity might not be fully explicable by exposure or MAC coin-
fection in TB patients.
MAC lung disease has been classified as two distinct subtypes,
the fibrocavitary and the nodular bronchiectatic forms. The fibro-
cavitary form is usually seen in middle-aged or elderly male alco-
holics and/or smokers with coexistent chronic obstructive pulmo-
nary disease (33). Chest radiography frequently demonstrates
apical cavity changes, similar to those in reactivated TB. This form
is generally progressive, and if left untreated can lead to extensive
lung destruction and/or death. The nodular bronchiectatic form
occurs predominantly in nonsmoking middle-aged or elderly fe-
males without previous or underlying lung disease (4, 34). In the
present study, of 175MAC-PD patients, 69 were classified as hav-
ing the nodular bronchiectatic form and 20 the fibrocavitary form
according to radiographic findings. Interestingly, fibrocavitary-
form patients showed significantly higher antibody responses to
three antigens than did those with the nodular bronchiectatic
form, and these antigens showed a greater sensitivity for patients
with the fibrocavitary form. The cavitary form is generally pro-
gressive and has a higher burden of bacteria than the nodular
bronchiectatic form (33). Therefore, cavitary disease with more-
severe manifestations may elicit strong antibody responses to an-
tigen. However, Kitada et al. (8) reported significantly higher an-
tibody levels to GPL in nodular bronchiectatic-form than in
fibrocavitary-form patients. To explain this discrepancy between
antibody responses in the two forms of MAC-PD, further multi-
variate analysis using more clinical cases is necessary.
The two MAC species,M. avium andM. intracellulare, are the
most frequently encountered causes of NTM pulmonary disease.
In fact, they are isolated equally frequently from MAC lung pa-
tients (34). Although these species are distinct and can be identi-
fied and distinguished using nucleic acid probes, they are pheno-
typically very similar. Moreover, demographic and radiographic
data and responses to therapy are indistinguishable between pa-
tients infected with these two species (33). Considering these clin-
ical similarities, the other interesting finding of our study was that
the antibody titers to four antigens in the M. intracellulare group
were higher than those in the M. avium group. Recently, it was
reported that patients withM. intracellulare lung disease exhibited
a more severe presentation than patients withM. avium lung dis-
ease (35). Therefore, patients with M. intracellulare PD are pre-
sumed to have extensive lung lesions, which is consistent with the
higher antibody responses in theM. intracellulare group.
It is generally accepted that multiple-antigen ELISAs can over-
come the low sensitivity of TB serodiagnosis that results from
individual heterogeneity in antibody responses. Rates of positivity
for two or more antigens within the same assay were 52%, 32.5%,
and 5.3% in MAC-PD, pulmonary TB, and HC subjects, respec-
tively. Rates of positivity for three antigenswere 32%and 17.1% in
MAC-PD and active TB subjects, respectively.HC subjects did not
react in assays that included three antigens. Finally, positivity rates
with at least one antigen were 65% and 76% of active TB and
MAC-PD subjects, respectively, with a specificity of 83%. These
results suggest that subjects who showed positivity for two or
more antigens were more likely to have MAC-PD or active TB.
Recently, NTM have been responsible for an increasing propor-
tion of mycobacterial lung disease in many developed countries
andMAC has been themost common cause of NTM lung disease.
Therefore, a cost-effective method for screening of mycobacterial
lung disease, including pulmonary TB and MAC-PD, is required.
Our findings suggest that an ELISA using the four antigens would
be helpful for screening for this disease, although further confir-
mation is needed to discriminate the disease-causing pathogens.
Further investigation on serological reactivity against the two
MAVantigens in the patients with otherNTM lung disease such as
M. kansasii is needed to develop amore reliable screeningmethod.
In conclusion, this is the first study to demonstrate the poten-
tial of MAV2054 and MAV5183 proteins as components of a se-
rological test for the diagnosis of TB aswell asMAC-PD. Although
TB antibody detection is not recommended for the diagnosis of
TB by the World Health Organization, it retains clinical value for
auxiliary diagnosis and is widely used in countries with a high
prevalence of TB. Therefore, multiple-antigen ELISAs that in-
clude MAV2054 and MAV5183 may facilitate diagnosis of MAC-
Shin et al.
300 cvi.asm.org Clinical and Vaccine Immunology
PD, in particular for smear- and culture-negative or culture- or
PCR-negative cases.
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